53Biologics

Executive Summary

53Biologics is a Spanish Contract Development and Manufacturing Organization (CDMO) founded in 2019, specializing in end-to-end biologics production including plasmid DNA and recombinant proteins. The company serves clients from preclinical through clinical stages, offering flexible services from cell line development to cGMP manufacturing and fill-finish. Based in Barcelona, 53Biologics leverages Spain's growing biotech ecosystem to provide cost-effective, high-quality biologics manufacturing to European and global clients. Its customer-focused model and expertise in both plasmid and protein production differentiate it in the competitive CDMO landscape. The biologics CDMO market is expanding rapidly, driven by increasing demand for gene therapies, vaccines, and monoclonal antibodies. 53Biologics is well-positioned to capture market share as biotechs seek reliable partners for scale-up and manufacturing. The company's ability to de-risk client projects by offering integrated services from DNA to drug product enhances its value proposition. With a lean cost structure and flexible approach, 53Biologics can attract early-stage companies needing rapid turnaround. In the near term, the company's success hinges on securing GMP certification, establishing anchor clients, and raising capital to expand capacity. As the European CDMO sector consolidates, 53Biologics has the potential to emerge as a key regional player in biologics production.

Upcoming Catalysts (preview)

• Q2 2027Achievement of GMP Certification at Barcelona Facility70% success
• Q4 2026Strategic Partnership with a Mid-Size Biotech for End-to-End Manufacturing50% success
• Q3 2026Series A Funding Round to Expand Capacity60% success